Gleevec

Imatinib

Designed to target cancer cells to alleviate disease progression.

Active ingredient
Imatinib
Supply
Rx
Route
Oral use
Form
Film-coated tablet
Strengths
100 · 400mg

Gleevec details

Alternative names
Glivec
Therapeutic class
Tyrosine Kinase Inhibitor
Pharmacological class
Tyrosine Kinase Inhibitor
Contraindications
hypersensitivity to imatinib
Minor side effects
nausea; muscle cramps; oedema; fatigue
Moderate side effects
diarrhoea; headache; neutropaenia
Dosage forms
Film-coated tablet
Administration route
Oral use
Patient summary
designed to target cancer cells to alleviate disease progression.
Supply category
Prescription only (specially controlled medicine)
Manufacturer
Novartis
Onset Time
2–4 hours
Duration
24 hours
Storage instructions
Store below 30°C.
Drug interactions
Ketoconazole; Warfarin; Grapefruit
Age restrictions
Used in children with specific leukaemic conditions.
Pregnancy and breastfeeding
Pregnancy: must not be used. Breastfeeding: not recommended.
Precautions and warnings

monitor blood counts regularly; avoid pregnancy during treatment; monitor liver function

Serious side effects

congestive heart failure, requires immediate medical attention; severe gastrointestinal haemorrhage, requires immediate medical attention

Mechanism of action

This medicine is a tyrosine kinase inhibitor that blocks specific proteins involved in the signalling pathways of cancer cell growth and survival.

Where this medicine is registered

  • Singapore
  • Hong Kong
  • Thailand
  • Malaysia
  • Philippines
  • Indonesia
  • Taiwan
  • South Korea
  • Japan
  • Australia
  • New Zealand
  • UAE
  • South Africa

About Gleevec

Gleevec is a primary brand of imatinib, used for the treatment of Chronic Myeloid Leukaemia and Gastrointestinal Stromal Tumour. This active ingredient is also distributed under the brand name Glivec. Produced by Novartis, the medication is supplied as a tablet in strengths of 100mg and 400mg.

Gleevec availability in Asia

Gleevec is registered across 14 markets including Indonesia, Taiwan and South Korea, with availability also in Japan, the UAE and Singapore. For expats or individuals residing far from a major medical hub, generic imatinib is often a more accessible option than the original brand. Much of this generic supply is produced in India, providing a consistent source for patients. As a targeted therapy, it is best used under a doctor’s care.